Hypophosphatemia in Prostate Cancer Patients Treated with Abiraterone
نویسندگان
چکیده
منابع مشابه
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.
BACKGROUND Metabolic syndrome (MS) has not yet been studied in castration-resistant prostate cancer (CRPC) men treated with novel hormonal therapies. The study aims to assess the impact of MS on outcome from time starting abiraterone. PATIENTS AND METHODS We retrospectively evaluated a consecutive series of metastatic CRPC patients treated with abiraterone after docetaxel failure. MS, as defi...
متن کاملChromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
In this retrospective study, we evaluated the chromogranin A (CgA) baseline value as a predictor of clinical outcome in patients with metastatic castration-resistant prostate cancer (CRPC) treated with abiraterone 1000 mg per day, whose disease progressed after docetaxel chemotherapy. In the 48 evaluable patients, serum CgA level was normal when <120 ng/ml (group A, n=16), within three times t...
متن کاملAbiraterone Boosts Prostate Cancer Survival
Final results of a phase III trial confirm that treatment with abiraterone prolongs overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) that has progressed after docetaxel therapy. Over a median 20 month follow-up, median OS was 15.8 months for abiraterone (Zytiga®) plus prednisone compared with 11.2 months for placebo plus the steroid (P<0.0001), Karim Fizazi, MD, ...
متن کاملInfluence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate
OBJECTIVE Even though the exact mechanism is largely unknown until now, statins are supposed to improve survival outcomes in various malignancies. For prostate cancer however, statins are known to compete with dehydroepiandrosterone (DHEAS) for the transport into the cytosol both using the cell by the Solute Carrier Transporter and thus diminish the cellular uptake of DHEAS as a precursor of an...
متن کاملWhich Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?
BACKGROUND Abiraterone acetate (AA) increases overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. However, survival time varies substantially between individuals. Our goal was to identify prognostic factors that better estimate OS. MATERIALS AND METHODS This is a retrospective multicentric analysis of 368 patients w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2015
ISSN: 0923-7534
DOI: 10.1093/annonc/mdv341.41